Literature DB >> 21088139

Dismounting the MDR horse.

Edward Libby1, Robert Hromas.   

Abstract

Entities:  

Year:  2010        PMID： 21088139     DOI： 10.1182/blood-2010-09-304311

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  11 in total

1.  High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.

Authors:  Benet Pera; M Nieves Calvo-Vidal; Srikanth Ambati; Michel Jordi; Alissa Kahn; J Fernando Díaz; Weishuo Fang; Karl-Heinz Altmann; Leandro Cerchietti; Malcolm A S Moore
Journal:  Cancer Lett       Date:  2015-08-12       Impact factor: 8.679

2.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

3.  Heterogeneity in refractory acute myeloid leukemia.

Authors:  Sachi Horibata; Gege Gui; Justin Lack; Christin B DeStefano; Michael M Gottesman; Christopher S Hourigan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-07       Impact factor: 11.205

4.  JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells.

Authors:  Yunmoon Oh; Jin-Sol Lee; Ji Sun Lee; Jae Hyeon Park; Hyung Sik Kim; Sungpil Yoon
Journal:  Int J Mol Sci       Date:  2022-04-21       Impact factor: 6.208

5.  Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Authors:  Chirayu Patel; Leif Stenke; Sudhir Varma; Marita Lagergren Lindberg; Magnus Björkholm; Jan Sjöberg; Kristina Viktorsson; Rolf Lewensohn; Ola Landgren; Michael M Gottesman; Jean-Pierre Gillet
Journal:  Cancer       Date:  2013-05-14       Impact factor: 6.860

6.  Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.

Authors:  John F Marcelletti; Branimir I Sikic; Larry D Cripe; Elisabeth Paietta
Journal:  Cytometry B Clin Cytom       Date:  2018-10-17       Impact factor: 3.058

Review 7.  Leukemia and ABC transporters.

Authors:  Yu Fukuda; Shangli Lian; John D Schuetz
Journal:  Adv Cancer Res       Date:  2015-01-08       Impact factor: 5.767

8.  The third-generation EGFR inhibitor almonertinib (HS-10296) resensitizes ABCB1-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.

Authors:  Chung-Pu Wu; Tai-Ho Hung; Sabrina Lusvarghi; Yi-Hsuan Chu; Sung-Han Hsiao; Yang-Hui Huang; Yu-Tzu Chang; Suresh V Ambudkar
Journal:  Biochem Pharmacol       Date:  2021-03-11       Impact factor: 6.100

9.  Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.

Authors:  Chung-Pu Wu; Megumi Murakami; Yu-Shan Wu; Ya-Chen Chi; Sung-Han Hsiao; Yang-Hui Huang; Tai-Ho Hung; Suresh V Ambudkar
Journal:  Front Cell Dev Biol       Date:  2021-07-19

10.  The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors.

Authors:  Jason Goebel; Jean Chmielewski; Christine A Hrycyna
Journal:  Cancer Drug Resist       Date:  2021-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.